mRNA 癌症疫苗的全球市場機會和臨床管道考慮因素 (2023)

Global mRNA Cancer Vaccines Market Opportunity & Clinical Pipeline Insight 2023

出版日期: 2023年08月01日 | 出版商:

KuicK Research | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

在投資和□□戰略聯盟激增以及對癌症治療突破的預期的推動下，全球 mRNA 癌症疫苗市場正在經歷重大的臨床和商業轉型。隨著製藥和生物技術公司認識到 mRNA 技術的潛力，在開發以前所未有的精度針對癌症的創新療法的前景的推動下，激烈的競爭正在逐漸發展，這種情況已經開始發生。

隨著製藥公司投入大量資源，將 mRNA 癌症疫苗從實驗階段推向可行的治療方案，研發投資正在擴大市場。初創公司和成熟的市場參與者都在追求 mRNA 癌症疫苗的各種優勢，包括快速適應性和針對呈遞特定抗原的癌細胞引發強烈免疫反應的潛力。

此外，世界領先的製藥公司和生物技術創新者之間的戰略聯盟正在塑造 mRNA 癌症疫苗的商業軌跡。 BioNTech 與 Genentech 以及 Moderna 與默克之間的合作是旨在開髮用於癌症適應症的新型 mRNA 疫苗的成功合作的例子。這些合作旨在通過結合雙方的專業知識，加速這些新型療法的開發、製造和分銷。此外，將 mRNA 疫苗納入多樣化的癌症領域管道中，正在提高每家公司在快速發展的癌症治療藥物市場中的競爭力。

mRNA癌症疫苗的吸引力導致眾多公司紛紛進入該市場以站穩腳跟。進入者數量的增加加劇了競爭並鼓勵了創新。每家公司都專注於開發自己的 mRNA 平台，並探索不僅針對現有癌症而且針對罕見癌症的應用。例如，BioNTech 的 FixVac 平台被用來開發該公司的五種 mRNA 癌症疫苗。該公司還有另一個平台，稱為 iNeST 平台。這兩個平台都可以開發個性化癌症疫苗。此外，競爭還提高了生產流程、定價策略和分銷網絡的效率。

然而，mRNA癌症疫苗的商業化過程中也存在需要仔細考慮的問題。定價策略必須在確保患者便利和為研發所需的大量投資提供回報之間取得微妙的平衡。有幾個因素影響抗癌藥物的成本。其中包括研發成本、製造複雜性、生產規模和產量、供應鏈物流、知識產權和許可。然而，預計各種 mRNA 癌症疫苗進入市場的競爭將有助於降低這些疫苗的價格。

此外，與監管機構打交道、確保知識產權、解決潛在的安全問題也是 mRNA 癌症疫苗成功進入市場的關鍵因素。首個基於 mRNA 的 COVID-19 疫苗的批准為後續 mRNA 療法（包括癌症療法）的更順利監管流程鋪平了道路。隨著世界各地的監管機構逐漸熟悉 mRNA 技術，進入市場所需的時間和資源可能會減少，從而促進商業化工作。

最後，市場不受地理邊界的限制。市場擴張戰略包括利用多元化的醫療保健生態系統以及與當地利益相關者合作。由於這些疫苗有助於證明其有效性和安全性，因此預計將在各種市場中得到採用，從而改變治療模式並為全球範圍內抗擊癌症做出貢獻。

市場前景廣闊，但同時也存在多方面問題需要解決。顯然，mRNA癌症疫苗有潛力產生重大臨床影響，但其商業化將取決於監管審批、市場接受度、報銷政策以及管理複雜供應鍊網絡的能力等因素。因此，市場是戰術規劃、協作和發現的大雜燴。了解全球擴張戰略、競爭動態、定價策略和投資趨勢之間複雜的相互作用對於佔領全球市場的重要份額至關重要。

本報告研究和分析了全球 mRNA 癌症疫苗市場，提供了對臨床管道、公司專有技術、合作夥伴關係和投資等方面的見解。

mRNA Cancer Vaccines Clinical Pipeline Insight: > 40 Vaccines In Trials
Highest Phase Of Clinical Development: Phase 3 (August 2023)
Till Now (August 2023) No Vaccines Is Commercially Approved In Market
mRNA Cancer Vaccines Clinical Pipeline Insight By Indication, Company, Country & Phase
RNA Cancer Vaccines Proprietary Technologies By Companies
Market Collaborations & Investments Insight

The clinical and commercial landscape of the global mRNA cancer vaccines market is undergoing a transformative shift marked by a surge in investment, strategic collaborations, and the anticipation of groundbreaking advancements in cancer treatment. As pharmaceutical and biotechnology companies recognize the potential of mRNA technology, a fierce competition is slowly unfolding, fuelled by the prospect of developing innovative therapies that target cancer with unprecedented precision.

Pharmaceutical companies are devoting significant resources into pushing mRNA cancer vaccines from the experimental stage to feasible therapeutic options, therefore the market is expanding as a result of research and development investments. Both start-ups and established market players are pursuing the various advantages of mRNA cancer vaccines, such as their fast adaptability and potential to trigger strong immune responses against cancer cells presenting a particular antigen.

Moreover, strategic partnerships between global pharmaceutical giants and biotechnology innovators are shaping the commercial trajectory of mRNA cancer vaccines. The collaborations between BioNTech and Genentech, and Moderna and Merck are prime examples of successful collaboration ventures aimed at the development of novel mRNA vaccines for cancer indications. Such collaborations aim to combine the expertise of both parties, accelerating the development, manufacturing and distribution of these novel therapies. Moreover, the inclusion of mRNA vaccines in diversified oncology pipelines is enhancing companies' overall competitiveness in the rapidly evolving cancer therapeutics market.

The allure of mRNA cancer vaccines has driven a wave of market entrants seeking to establish a strong foothold. The influx of players has led to heightened competition, fostering innovation. Companies are focusing on developing proprietary mRNA platforms, targeting not only established cancers but also exploring applications in rarer cancer indications. For instance, BioNTech's FixVac platform has been used to develop 5 of the company's mRNA cancer vaccines. The company has another platform, called the iNeST platform. Both platforms allow the developed of individualized cancer vaccines. In addition, the competition has also increased the efficiency in production processes, pricing strategies and distribution networks.

However, commercialization of mRNA cancer vaccines presents challenges that necessitate careful consideration. Pricing strategies must strike a delicate balance between ensuring patient accessibility and providing a return on the substantial investments required for research and development. Several factors influence the cost of a cancer therapeutic. These include research and development costs, manufacturing complexities, production scale and volume, supply chain logistics, intellectual property and licensing. However, it is also expected the competition resulting from increasing market entry of different mRNA cancer vaccines will help these vaccines be sold at affordable prices.

In addition, navigating regulatory pathways, securing intellectual property rights and addressing potential safety concerns are also critical components in successfully bringing mRNA cancer vaccines to the market. The approval of the first mRNA-based COVID-19 vaccines has paved the way for a smoother regulatory process for subsequent mRNA therapies, including those for cancer. As regulatory agencies around the world become more familiar with mRNA technology, the time and resources required for market entry may potentially decrease, expediting commercialization efforts.

Lastly, the global mRNA cancer vaccines market is not confined by geographical boundaries. Market expansion strategies involve penetrating diverse healthcare ecosystems and collaborating with regional stakeholders. As these vaccines contribute to demonstrate their efficacy and safety, their adoption across different markets holds the promise of changing treatment paradigms and contributing to the fight against cancer on a global scale.

The global market for mRNA cancer vaccines has a promising future but it also has different aspects that need to be addressed. Even while the potential for a substantial clinical impact of mRNA cancer vaccines is obvious, their commercialization will be dependent on factors such as regulatory clearance, market acceptance, reimbursement policies, and the ability to manage complex supply chain networks. Therefore, the global market for mRNA cancer vaccines is a mosaic of tactical planning, collaborations, and discoveries. Understanding the complex interactions between global expansion strategies, competitive dynamics, pricing strategies and investment trends in critical to be able to grab a sizeable market share in the global market.

1. mRNA Vaccines as Next Generation Cancer Immunotherapy

1.1 mRNA Vaccines Overview
1.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches
1.3 mRNA Vaccines v/s Other Vaccines

2. Global mRNA Cancer Vaccines Market Overview

2.1 Current Market Landscape
2.2 Future Clinical & Commercialization Opportunities

3. Global mRNA Cancer Vaccines Market Trends by Country

3.1 US
3.2 China
3.3 Australia
3.4 Europe
3.5 Canada

4. Global mRNA Cancer Vaccines Market Collaborations, Deals & Investments

5. Global mRNA Cancer Vaccines Market Clinical Landscape by Indication

5.1 Breast Cancer
5.2 Brain Cancer
5.3 Melanoma
5.4 Colorectal Cancer
5.5 Head & Neck Cancers

6. Global mRNA Cancer Vaccines Clinical Pipeline Overview

6.1 By Company
6.2 By Country
6.3 By Patient Segment
6.4 By Phase
6.5 By Priority Status

7. Global mRNA Cancer Vaccines Clinical Pipeline By Company, Indication & Phase

7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III

8. Proprietary Technologies & Methodologies for RNA Cancer Vaccines Development

8.1 FixVac - BioNTech
8.2 iNeST - BioNTech
8.3 NanoReady - Samyang Holdings
8.4 CureVac Method - CureVac
8.5 mRNA platform - Moderna
8.6 NeoCura Ag - NeoCura

9. Competitive Landscape

9.1 Avstera Therapeutics
9.2 BioNTech
9.3 Combined Therapeutics
9.4 CureVac
9.5 EpiVax
9.6 Immorna
9.7 Immune Design
9.8 MDimune
9.9 Moderna Therapeutics
9.10 NeoCura
9.11 Orna Therapeutics
9.12 pHion Therapeutics
9.13 Regen BioPharma
9.14 RNAimmune
9.15 TransCode Therapeutics

簡介目錄圖表

List of Figures

Figure 5-1: KEYNOTE-603 Phase I Study - Initiation & Completion Years
Figure 5-2: GO39733 Phase I Study - Initiation & Completion Years
Figure 5-3: ATTAC-II Phase II Study - Initiation & Completion Years
Figure 5-4: CV-GBLM-001 Phase I Study - Initiation & Completion Years
Figure 5-5: GO39733 Phase II Study - Initiation & Completion Years
Figure 5-6: BNT111-01 Phase II Study - Initiation & Completion Years
Figure 5-7: BNT122-01 Phase II Study - Initiation & Completion Years
Figure 5-8: AHEAD-MERIT Phase II Study - Initiation & Completion Years
Figure 5-9: KEYNOTE-603 Phase II Study - Initiation & Completion Years
Figure 6-1: Global - mRNA Cancer Vaccines Clinical Pipeline by Company (Numbers), 2023
Figure 6-2: Global - mRNA Cancer Vaccines Clinical Pipeline by Country (Numbers), 2023
Figure 6-3: Global - mRNA Cancer Vaccines Clinical Pipeline by Patient Segment (Numbers), 2023
Figure 6-4: Global - mRNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2023
Figure 6-5: Global - mRNA Cancer Vaccines Clinical Pipeline by Priority Status (Numbers), 2023
Figure 8-1: BioNTech - uRNA products
Figure 8-2: BioNTech - iNeST technology
Figure 8-3: CureVac - CureVac Method for Generation of mRNA Therapeutics
Figure 8-4: Moderna - mRNA Technology
Figure 8-5: NeoCura - NeoCura Ag Platform